12 Month Price Forecast For INNV
Distance to INNV Price Forecasts
INNV Price Momentum
๐ค Considering Innovus (INNV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 4:26 PM UTC
INNV Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, INNV has a neutral consensus with a median price target of $5.25 (ranging from $5.00 to $5.50). The overall analyst rating is Hold (5.5/10). Currently trading at $3.39, the median forecast implies a 54.9% upside. This outlook is supported by 0 Buy, 3 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Lisa Gill at JP Morgan, suggesting a 47.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INNV Analyst Consensus
INNV Price Target Range
Latest INNV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INNV.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 17, 2024 | JP Morgan | Lisa Gill | Underweight | Downgrade | $5.00 |
Oct 11, 2024 | Keybanc | Matthew Gillmor | Sector Weight | Initiates | $0.00 |
Mar 13, 2024 | JP Morgan | Lisa Gill | Neutral | Maintains | $6.00 |
Feb 8, 2024 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $7.00 |
Feb 15, 2023 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $9.00 |
Feb 8, 2023 | JP Morgan | Lisa Gill | Neutral | Maintains | $8.00 |
Nov 23, 2022 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $8.00 |
Nov 16, 2022 | Citigroup | Jason Cassorla | Neutral | Maintains | $8.00 |
Sep 15, 2022 | Barclays | Sarah James | Equal-Weight | Maintains | $5.00 |
May 16, 2022 | Baird | Vikram Kesavabhotla | Neutral | Downgrade | $5.00 |
May 11, 2022 | Piper Sandler | Jeff Garro | Underweight | Maintains | $3.90 |
Apr 20, 2022 | Piper Sandler | Jeff Garro | Underweight | Downgrade | $5.00 |
Dec 28, 2021 | Goldman Sachs | Jamie Perse | Neutral | Downgrade | $4.00 |
Dec 27, 2021 | Barclays | Sarah James | Equal-Weight | Downgrade | $6.50 |
Dec 17, 2021 | JP Morgan | Neutral | Initiates | $0.00 | |
Sep 29, 2021 | Citigroup | Neutral | Downgrade | $0.00 | |
Sep 22, 2021 | William Blair | Market Perform | Downgrade | $0.00 | |
Sep 10, 2021 | Cowen & Co. | Market Perform | Initiates | $0.00 | |
Aug 12, 2021 | Barclays | Steve Valiquette | Overweight | Upgrade | $19.00 |
May 28, 2021 | Baird | Outperform | Initiates | $0.00 |
Stocks Similar to Innovus Pharmaceuticals, Inc.
The following stocks are similar to Innovus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Innovus Pharmaceuticals, Inc. (INNV) Financial Data
Innovus Pharmaceuticals, Inc. has a market capitalization of $467.94M with a P/E ratio of -21.2x. The company generates $806.61M in trailing twelve-month revenue with a -3.2% profit margin.
Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of -1.9% and return on equity of -9.5%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Innovus Pharmaceuticals, Inc. (INNV) Company Overview
About Innovus Pharmaceuticals, Inc.
Provides comprehensive care services for seniors.
The company operates through the Program of All-Inclusive Care for the Elderly (PACE), which allows it to provide a range of medical and ancillary services to seniors. InnovAge generates revenue primarily through government reimbursements and payments for the services provided to its participants, ensuring they can live independently while receiving necessary care.
InnovAge serves participants across multiple states, including Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company has a strong focus on in-home care and offers various services such as primary care, therapy, and transportation, positioning itself as a comprehensive solution for elderly care. Founded in 2007 and headquartered in Denver, it rebranded from TCO Group Holdings, Inc. in January 2021.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
2,350
CEO
Mr. Patrick Blair
Country
United States
IPO Year
2020
Website
www.innovage.comInnovus Pharmaceuticals, Inc. (INNV) Latest News & Analysis
InnovAge Holding Corp. will host its Q2 2025 earnings conference call on February 4, 2025, at 5:00 PM ET, featuring key executives and analysts from major financial firms.
InnovAge's Q2 2025 earnings call indicates financial performance insights, potential growth opportunities, and market sentiment, influencing stock valuation and investment decisions.
InnovAge Announces Financial Results For the Fiscal Second Quarter Ended December 31, 2024
11 days agoInnovAge Holding Corp. reported its fiscal Q2 results for the period ending December 31, 2024, highlighting progress in business strength, top-line growth, and margin improvement.
InnovAge's positive financial results indicate growth and improved margins, signaling potential for increased profitability and investment appeal in the healthcare sector for seniors.
InnovAge Holding Corp. will release its fiscal Q2 2025 financial results on February 4, 2025, after market close, followed by a conference call at 5 p.m. that day.
The upcoming earnings release and conference call for InnovAge may significantly impact stock performance, providing insights into financial health and future growth potential in the senior healthcare market.
InnovAge Holding Corp. (NASDAQ: INNV) will discuss its Q1 2025 results in a conference call on November 5, 2024, at 5:00 PM ET with key executives participating.
InnovAge's Q1 2025 earnings results can influence stock performance, investor sentiment, and analyst ratings. Key insights from executives can impact future growth expectations.
InnovAge Holding Corp. appointed Michael Scarbrough as President and COO, and Maria Lozzano as President of Pharmacy Services, effective November 4, 2024.
Leadership changes at InnovAge may signal strategic shifts that could impact operational efficiency and growth, influencing investor confidence and stock performance.
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2024
3 months agoInnovAge Holding Corp. reported its fiscal Q1 results for the period ending September 30, 2024, highlighting ongoing growth and improved margins in providing healthcare for seniors.
InnovAge's strong fiscal first quarter results indicate effective strategy execution and margin improvement, signaling potential growth and stability, which can influence investor confidence and stock performance.
Frequently Asked Questions About INNV Stock
What is Innovus Pharmaceuticals, Inc.'s (INNV) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Innovus Pharmaceuticals, Inc. (INNV) has a median price target of $5.25. The highest price target is $5.50 and the lowest is $5.00.
Is INNV stock a good investment in 2025?
According to current analyst ratings, INNV has 0 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $3.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for INNV stock?
Wall Street analysts predict INNV stock could reach $5.25 in the next 12 months. This represents a 54.9% increase from the current price of $3.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Innovus Pharmaceuticals, Inc.'s business model?
The company operates through the Program of All-Inclusive Care for the Elderly (PACE), which allows it to provide a range of medical and ancillary services to seniors. InnovAge generates revenue primarily through government reimbursements and payments for the services provided to its participants, ensuring they can live independently while receiving necessary care.
What is the highest forecasted price for INNV Innovus Pharmaceuticals, Inc.?
The highest price target for INNV is $5.50 from at , which represents a 62.2% increase from the current price of $3.39.
What is the lowest forecasted price for INNV Innovus Pharmaceuticals, Inc.?
The lowest price target for INNV is $5.00 from Lisa Gill at JP Morgan, which represents a 47.5% increase from the current price of $3.39.
What is the overall INNV consensus from analysts for Innovus Pharmaceuticals, Inc.?
The overall analyst consensus for INNV is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $5.25.
How accurate are INNV stock price projections?
Stock price projections, including those for Innovus Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.